touchONCOLOGY were delighted to talk to Prof. Ken Kato to discuss long-term safety and efficacy data from the ATTRACTION-1 study will support the potential role of nivolumab in esophageal squamous cell carcinoma.
The abstract ‘Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up’ (Abstract number 207) was presented at ASCO’s virtual Gastrointestinal Cancers Symposium 2021,15-–17 January 2021.
- Could you tell us a little about the ATTRACTION-1 study and its findings? (0:30)
- What has the latest data shown us about the long-term efficacy and safety of nivolumab in advanced esophageal squamous cell carcinoma? (2:07)
- Could you give us a brief overview of the ATTRACTION clinical trial programme and other future and ongoing clinical studies in the trial? (4:20)
Disclosures: Prof. Ken Kato has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of ASCO’s Gastrointestinal Cancers Symposium 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Oncology
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Jean-Luc Van Laethem, ASCO GI 2021: Pembrolizumab for Advanced Hepatocellular Carcinoma
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!